Pasithea Therapeutics - Warrants (11/08/2026) Operating Income

The latest operating income for KTTAW is $-35B as of June 2026. That compares with $-6.7B in the prior-year period — down 416.2% year over year. Investors often review this figure alongside Pasithea Therapeutics - Warrants (11/08/2026)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, KTTAW's operating income moved from $-6.7B to $-35B — a 416.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pasithea Therapeutics - Warrants (11/08/2026)'s operating scale or balance-sheet position.

A operating income figure of $-35B for KTTAW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting KTTAW's operating income ($-35B), review year-over-year change from $-6.7B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Pasithea Therapeutics - Warrants (11/08/2026)'s operating income against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.